CRMD logo

CorMedix Inc. Stock Price

NasdaqGM:CRMD Community·US$637.6m Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 121 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

CRMD Share Price Performance

US$8.13
-4.66 (-36.43%)
​
US$13.00
Fair Value
US$8.13
-4.66 (-36.43%)
37.5% undervalued intrinsic discount
US$13.00
Fair Value
Price US$8.13
MRT23 US$13.00
AnalystConsensusTarget US$15.20
AnalystHighTarget US$19.00

CRMD Community Narratives

Fair Value
·
Fair Value US$13 37.5% undervalued intrinsic discount

CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events

1users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
Fair Value
·
Fair Value US$15.2 46.5% undervalued intrinsic discount

Acquisition And Pipeline Expansion Will Unlock Healthcare Potential

1users have liked this narrative
0users have commented on this narrative
40users have followed this narrative
Fair Value
·
Fair Value US$19 57.2% undervalued intrinsic discount

Long Term Infection Prevention Demand Will Drive Expanding Cash Generation And Durable Market Leadership

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
CRMD logo
CorMedix
37.5% undervalued intrinsic discount

CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events

View narrative
Updated 13 Aug
Read Narrative
CRMD logo
CorMedix
46.5% undervalued intrinsic discount

Acquisition And Pipeline Expansion Will Unlock Healthcare Potential

View narrative
Updated 17 Jun
Read Narrative
CRMD logo
CorMedix
57.2% undervalued intrinsic discount

Long Term Infection Prevention Demand Will Drive Expanding Cash Generation And Durable Market Leadership

View narrative
Updated 1 Jul
Read Narrative
CRMD logo
CorMedix
41.9% undervalued intrinsic discount

Hospital Anti-Infective Demand Will Face Reimbursement Headwinds Yet Ultimately Support Modest Upside

View narrative
Published 27 Dec 2025
Read Narrative

Trending Discussion

No trending discussion available.

Updated Narratives

CRMD logo

CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events

Fair Value: US$13 37.5% undervalued intrinsic discount
13 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CRMD logo

CRMD: Future Anti Infective Portfolio Expansion Will Drive Re Rating Potential

Fair Value: US$19 57.2% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CRMD logo

CRMD: Raised 2026 Guidance And Late-Stage Pipeline Progress Will Support Undervalued Shares

Fair Value: US$15.2 46.5% undervalued intrinsic discount
40 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with solid track record.

1 Risk
4 Rewards
View Full Analysis

CorMedix Inc. Key Details

US$462.2m

Revenue

US$45.2m

Cost of Revenue

US$417.0m

Gross Profit

US$231.0m

Other Expenses

US$186.0m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
2.39
90.21%
40.24%
31.5%
View Full Analysis

About CRMD

Founded
2006
Employees
191
CEO
Joseph Todisco
WebsiteView website
cormedix.com

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

Recent CRMD News & Updates

Seeking Alpha • Aug 18

CorMedix: Durable Commercial Base, But 2027 Is The Real Test

Summary CorMedix Inc. has transitioned into a profitable, cash-generating commercial business, driven by DefenCath's resilient demand and full access across top U.S. dialysis providers. CRMD's 2Q26 results showed consolidated revenue of $101.9M (+157% YoY), strong EBITDA generation ($58.7M), and a robust balance sheet with $256.7M in cash. Valuation remains deeply discounted (EV/EBITDA 1.8x), reflecting market skepticism about post-2026 earnings durability amid evolving reimbursement and adoption dynamics. I maintain a Hold rating as visibility into 2027 growth drivers—LDO ramp, Medicare Advantage uptake, and ESRD reimbursement—remains limited, balancing strong current fundamentals with forward uncertainty. Read the full article on Seeking Alpha

Recent updates

No updates

CorMedix Inc. Competitors

VERA logo

Vera Therapeutics

Symbol: NasdaqGM:VERA
Market cap: US$2.5b
OCUL logo

Ocular Therapeutix

Symbol: NasdaqGM:OCUL
Market cap: US$2.5b
SUPN logo

Supernus Pharmaceuticals

Symbol: NasdaqGM:SUPN
Market cap: US$2.5b
PGEN logo

Precigen

Symbol: NasdaqGS:PGEN
Market cap: US$2.5b
View more competitors